Stoke Therapeutics Management

Management criteria checks 3/4

Stoke Therapeutics' CEO is Ed Kaye, appointed in Oct 2017, has a tenure of 6.5 years. total yearly compensation is $3.53M, comprised of 17.7% salary and 82.3% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth €757.57K. The average tenure of the management team and the board of directors is 5.1 years and 5.6 years respectively.

Key information

Ed Kaye

Chief executive officer

US$3.5m

Total compensation

CEO salary percentage	17.7%
CEO tenure	6.5yrs
CEO ownership	0.1%
Management average tenure	5.1yrs
Board average tenure	5.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ed Kaye's remuneration changed compared to Stoke Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$4m	US$626k	-US$105m
Sep 30 2023	n/a	n/a	-US$103m
Jun 30 2023	n/a	n/a	-US$105m
Mar 31 2023	n/a	n/a	-US$99m
Dec 31 2022	US$6m	US$596k	-US$101m
Sep 30 2022	n/a	n/a	-US$100m
Jun 30 2022	n/a	n/a	-US$96m
Mar 31 2022	n/a	n/a	-US$94m
Dec 31 2021	US$9m	US$568k	-US$86m
Sep 30 2021	n/a	n/a	-US$76m
Jun 30 2021	n/a	n/a	-US$67m
Mar 31 2021	n/a	n/a	-US$58m
Dec 31 2020	US$5m	US$549k	-US$52m
Sep 30 2020	n/a	n/a	-US$48m
Jun 30 2020	n/a	n/a	-US$43m
Mar 31 2020	n/a	n/a	-US$38m
Dec 31 2019	US$668k	US$477k	-US$32m
Sep 30 2019	n/a	n/a	-US$26m
Jun 30 2019	n/a	n/a	-US$21m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$1m	US$464k	-US$13m

Compensation vs Market: Ed's total compensation ($USD3.53M) is above average for companies of similar size in the German market ($USD1.29M).

Compensation vs Earnings: Ed's compensation has been consistent with company performance over the past year.

CEO

Ed Kaye (74 yo)

6.5yrs

Tenure

US$3,533,210

Compensation

Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Edward Kaye	CEO & Director	6.5yrs	US$3.53m	0.13% $ 757.6k
Adrian Krainer	Co-Founder & Independent Director	no data	US$198.33k	0.78% $ 4.4m
Isabel Aznarez	Co-Founder & Group VP of Discovery Research	no data	no data	no data
Stephen Tulipano	Chief Financial Officer	5.1yrs	US$1.60m	0.040% $ 226.6k
Huw Nash	COO & Chief Business Officer	6.5yrs	US$869.86k	no data
Eric Rojas	Head of Investor Relations	no data	no data	no data
Jonathan Allan	Corporate Secretary & General Counsel	3.3yrs	no data	0.0050% $ 28.4k
Dawn Kalmar	Chief Communications Officer	3.3yrs	no data	no data
Joan Wood	Chief Human Resources Officer	4.5yrs	no data	no data
Barry Ticho	Chief Medical Officer	6.5yrs	US$1.65m	0.0048% $ 27.1k
Shamim Ruff	Chief Regulatory Officer	5.3yrs	no data	no data
Jason Hoitt	Chief Commercial Officer	no data	no data	no data

5.1yrs

Average Tenure

59yo

Average Age

Experienced Management: 0GT's management team is seasoned and experienced (5.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Edward Kaye	CEO & Director	6.5yrs	US$3.53m	0.13% $ 757.6k
Adrian Krainer	Co-Founder & Independent Director	9.8yrs	US$198.33k	0.78% $ 4.4m
Seth Harrison	Independent Chairman of the Board	8.8yrs	US$237.33k	3.62% $ 20.5m
Arthur Levin	Independent Director	8.6yrs	US$198.33k	0.035% $ 196.4k
Ian Smith	Independent Director	less than a year	US$394.03k	no data
Garry Menzel	Independent Director	3.7yrs	US$199.33k	0% $ 0
Julie Smith	Independent Director	3.8yrs	US$206.83k	0% $ 0
Jennifer Burstein	Independent Director	4.8yrs	US$209.33k	0% $ 0
Arthur Tzianabos	Independent Director	5.6yrs	US$211.83k	0.061% $ 346.7k

5.6yrs

Average Tenure

60yo

Average Age

Experienced Board: 0GT's board of directors are considered experienced (5.6 years average tenure).

Stoke Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Stoke Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics, Inc. Appoints Ian Smith to Board of Directors

Insufficient new directors

High number of new directors

High number of new directors

Recent updates

Stoke Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000004 million.

Stoke Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000005 million.

Stoke Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: US$2.38 loss per share (vs US$2.60 loss in FY 2022)

New major risk - Share price stability

New major risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.55 loss per share (vs US$0.66 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Stoke Therapeutics, Inc. Appoints Ian Smith to Board of Directors

Stoke Therapeutics, Inc. Presents Data Related to the Ongoing Clinical Development of Stk-001 for the Treatment of Dravet Syndrome

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$0.63 loss in 2Q 2022)

New major risk - Revenue and earnings growth

Stoke Therapeutics, Inc. Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (Monarch & Adolescents with Dravet Syndrome

Insufficient new directors

Stoke Therapeutics, Inc. Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

High number of new directors

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell 2000 Growth Index

Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and Opa1 Protein Upregulation in Retinal Tissue Following Administration of Stk-002

High number of new directors

Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome

Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)

New 90-day high: €52.50

New 90-day high: €46.00

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

Stoke Therapeutics, Inc. Announces Resignation of Robin A. Walker, Senior Vice President, Chief Legal Officer and Chief Compliance Officer

New 90-day high: €34.20

New 90-day high: €32.20

Stoke Therapeutics, Inc. Announces Plans to Move Forward with Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a Monarch Study for Dravet Syndrome

New 90-day high - €26.80

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age